Antenatal Thyrotropin-Releasing Hormone for Lung Disease Prevention in Preterm Infants
thyrotropin-releasing hormone
Lung Diseases+7
+ Congenital, Hereditary, and Neonatal Diseases and Abnormalities
+ Pathologic Processes
Treatment Study
Summary
Study start date: May 1, 1998
Actual date on which the first participant was enrolled.PROTOCOL OUTLINE: This is a randomized, double blind, multicenter study. Patients are randomized to receive antenatal thyrotropin-releasing hormone or placebo. Patients receive thyrotropin-releasing hormone or placebo intravenously over 20 minutes every 8 hours for 4 doses. Infants are assessed for survival and chronic lung disease until day 28 after birth, and again at 36 postmenstrual weeks.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.996 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Female
Biological sex of participants that are eligible to enroll.From 20 to 36 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Pregnant women in active labor with 24-29 weeks gestation Not eligible if any of the following is present: Bleeding Infection Hypertension (greater than 140/90 mmHg) Fetus with hydrops or life-threatening anomalies One dead fetus in multiple pregnancy